Duvelisib (1201438-56-3) is a potent and selective (IC50s: PI3Kalpha = 1602nM, PI3Kbeta = 85nM, PI3Kdelta= 2.5nM, PI3Kgamma = 27nM) dual PI3Kdelta/gamma inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor crosslinking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2 Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, ande others.3,4 Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5 Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes
* VAT and and shipping costs not included. Errors and price changes excepted
